Similar articles

• Cardiovascular effects of ATG and OKT3 in renal allograft recipients.

  Spieker C, Barenbrock M, Buchholz B, Heidenreich S, Zidek W. Spieker C, et al. Transplant Proc. 1992 Dec;24(6):2594-5. Transplant Proc. 1992. PMID: 1465876 Clinical Trial. No abstract available.
• [Differential diagnosis of transplant function disorders in therapy with monoclonal antibodies OKT3].

  Müller T, Keuchel M, Schindler S, Steinmetz A, Feiber H, Lange H. Müller T, et al. Helv Chir Acta. 1991 Sep;58(3):271-5. Helv Chir Acta. 1991. PMID: 1769844 German.
• Measures to improve early results in kidney transplantation.

  Schweizer RT, Roper L, Hull D, Bartus S. Schweizer RT, et al. Transplant Proc. 1992 Dec;24(6):2729-30. Transplant Proc. 1992. PMID: 1465919 No abstract available.
• Minimizing the toxicity of antilymphocyte antibody therapy.

  Pascual M, Rubin RH, Cosimi AB. Pascual M, et al. Transplant Proc. 1996 Aug;28(4):2113-4. Transplant Proc. 1996. PMID: 8769171 Review. No abstract available.
• Sequential therapy in pediatric cadaveric renal transplantation: a critical analysis.

  Ettenger R, Marik J, Rosenthal JT. Ettenger R, et al. J Am Soc Nephrol. 1992 Jun;2(12 Suppl):S304-11. doi: 10.1681/ASN.V212s304. J Am Soc Nephrol. 1992. PMID: 1498290 Review.